Lyell and CRISPR Tx Present Novel CAR-Ts in Solid Tumors; SITC 2023 Analysis 2
Here is a brief preview of this blast: SITC 2023 Analysis 2: Lyell and CRISPR Tx presented preclinical results from their novel cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered: